A pooled analysis involving 2310 HER2-negative BC patients from four prospective neoadjuvant clinical trials evidenced that HER2-low status seems to have a prognostic role; particularly, low expression of HER2 was significantly associated with a better DFS and OS, a lower number of grade III tumors, lower Ki-67 scores, and a reduced number of TP53 mutations compared with HER2 IHC score 0 BCs [100]. This evidence concerns the gene ERBB2 and breast cancer.